ScioScientific LLC

12/28/2025

New York City’s supervised drug consumption site OnPoint says it will continue operating despite federal pressure, a bold stand in the ongoing effort to reduce overdoses and support harm-reduction approaches. As communities across the country grapple with substance use and public health strategy, this move highlights the real-world impact of compassionate, evidence-based care. Here's more on this.

OnPoint, the nation's first supervised drug consumption site, vows to continue its approach to harm reduction.

12/25/2025

Merry Christmas from ScioScientific LLC! Wishing our partners, clients, and community a season filled with peace, joy, and renewed hope. Thank you for being part of our journey.

12/23/2025

Some employers are dropping coverage for popular weight-loss drugs like Wegovy and Zepbound, even as pharma pushes direct-to-consumer programs that may still leave many workers paying high cash prices. It highlights ongoing challenges in access to affordable medicines and how health plans are adapting to rising demand and costs. Here's more on this.

Doctors and groups representing employers said they’re increasingly hearing about companies cutting weight loss drugs out of health plans next year.

12/22/2025

Lessons from the AIDS crisis remind us that research can’t wait for politics, when federal funding dries up, scientists and advocates must find ways to keep vital work going through community collaboration, alternative funding, and shared data, just as activists did in the 1980s.
We need resilience, innovation, and commitment to sustain progress against HIV and other major health threats even in difficult funding environments. Read more on this.

Here are five things that actually work when there’s no federal funding for critical research.

12/21/2025

New data on Eli Lilly’s obesity pill Orforglipron show it might help people not just lose weight but keep it off which is a big deal in the long journey of obesity treatment.
As research evolves, these breakthroughs could change how we think about sustainable weight management and metabolic health. Read more on this.

Eli Lilly's obesity pill helped patients maintain weight loss after they switched from injectable drugs, outcomes that could widen the appeal of the pill.

12/19/2025

Entrepreneur Vivek Ramaswamy and Ambros Therapeutics are launching a new effort to develop a treatment for complex regional pain syndrome (CRPS), a chronic, often debilitating condition that affects many people’s quality of life. If successful, this could be a meaningful step forward for patients who currently have very few effective options. Here's more on this.

Ambros Therapeutics, Vivek Ramaswamy'a latest startup, launches with plans for pain treatment.

12/17/2025

New developments in health tech could make your routine mammogram more powerful than ever. Researchers and companies are exploring AI tools that not only help detect existing breast cancer but also predict future risk for breast cancer and heart disease from the same image.
If this works out, it could transform preventive care by identifying risks earlier and more accurately. Here's more on this.

A new generation of AI algorithms aim to go beyond detecting cancers to predicting risk for cardiovascular diseases.

12/16/2025

A senior Trump administration official is using an executive order to sidestep a state law regulating artificial intelligence, a move that’s raising fresh concerns about federal power, tech oversight, and how AI should be governed. Read more on this.

Deputy health secretary Jim O’Neill demurred when asked about a proposal to prevent states from enforcing local AI laws.

12/15/2025

At the American Society of Hematology meeting, researchers highlighted promising data on a higher‑dose sickle cell pill that boosted fetal hemoglobin levels, a potential step forward in oral treatments, and new approaches to myelofibrosis care were also discussed.
These developments show how innovation in blood‑disease research continues to advance at major clinical conferences. Read more on this.

At ASH 2025, Fulcrum presented promising data on a sickle cell pill and Incyte is pioneering a new way to treat myelofibrosis.

12/14/2025

Cancer‑detection biotech Freenome is planning to go public through a S**C deal as it pushes forward with blood‑based tests that aim to detect cancer early, potentially transforming how we screen for the disease and catch it when treatment can be most effective. Read more on this.

Freenome, a Bay Area biotech that is part of the increasingly competitive race to accurately detect cancer early through blood-based tests, plans to go public.

12/13/2025

The CDC’s vaccine advisory panel has voted to overturn a 30‑year‑old hepatitis B vaccination policy, ending the long‑standing recommendation to give the first dose at birth. Supporters say it could reduce immediate vaccine reactions, but many public‑health experts worry this change could lead to more preventable infections.
It’s a big shift in immunization policy with real implications for families and public health. Here's more on this.

The CDC's ACIP panel voted to recommend delaying the birth dose of the hepatitis B vaccine, ending a policy that has reined in the virus.

12/12/2025

The FDA’s top vaccine regulator, Vinay Prasad, is defending his controversial vaccine policy changes and pushing back against critics, saying misleading media narratives have fueled much of the backlash, even as former FDA leaders and public health experts raise serious concerns.
This highlights the ongoing debate around how we balance vaccine safety, science, and public trust. Read more on this.

https://www.statnews.com/2025/12/04/vinay-prasad-fda-defends-vaccine-plan-blames-false-narratives/